Stock Events

Stock Events

Vir Biotechnology 

$11.39
135
-$0.06-0.57% Friday 20:00
+$0.12+1.01%Friday 23:47After hours

Statistics

Day High
11.41
Day Low
11.37
52W High
11.94
52W Low
4.75
Volume
25,323
Avg. Volume
-
Mkt Cap
1.93B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 10
$0.03
Sep 10
$0.03
Jun 10
$0.03
Mar 10
$0.03
Dec 9
$0.03
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.17
-0.62
-0.08
0.47
Expected EPS
-0.73934
Actual EPS
N/A

Financials

-638.87%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
68.56MRevenue
-437.99MNet Income

Analyst Ratings

24.00Average Price Target
The highest estimate is 27.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VIR. It's not an investment recommendation.
Apple
29
AAPL
Microsoft
28
MSFT
Tesla
25
TSLA
NVIDIA
25
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a direct competitor in the antiviral drug market, focusing on treatments for HIV, hepatitis B, hepatitis C, and influenza, similar to Vir's focus on infectious diseases.
Moderna
MRNA
Mkt Cap55.09B
Moderna is known for its mRNA technology used in vaccines, directly competing with Vir's efforts in developing treatments and vaccines for infectious diseases.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the infectious disease space with its mRNA technology for vaccines, similar to Vir's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes with Vir in developing monoclonal antibodies for the treatment of infectious diseases, including COVID-19.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a competitor in the vaccine space, particularly for COVID-19, directly competing with Vir's efforts in infectious disease vaccines.
Pfizer
PFE
Mkt Cap159.36B
Pfizer competes across a broad range of therapeutic areas including vaccines for infectious diseases, making it a competitor to Vir.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and treatments for infectious diseases.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in the development of vaccines and treatments for various infectious diseases, competing with Vir's focus areas.
Sanofi
SNY
Mkt Cap107.39B
Sanofi competes with Vir in the infectious disease sector, particularly in the development of vaccines and treatments for various diseases.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories competes with Vir in the broader healthcare sector, including diagnostics and treatments for infectious diseases.

About

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Show more...
CEO
Marianne De Backer
Employees
367
Country
United States
ISIN
US92764N1028

Listings

XNAS
US
VIR
MX
MX
VIR.MX
BOATS
BOATS
VIR.BOATS

0 Comments

Share your thoughts

FAQ

What is Vir Biotechnology stock price today?▼
The current price of VIR is $11.39 USD — it has decreased by -0.57% in the past 24 hours. Watch Vir Biotechnology stock price performance more closely on the chart.
What is Vir Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vir Biotechnology stocks are traded under the ticker VIR.
Is Vir Biotechnology stock price growing?▼
VIR stock has risen by +5.12% compared to the previous week, the month change is a +24.97% rise, over the last year Vir Biotechnology has showed a +116.03% increase.
What is Vir Biotechnology market cap?▼
Today Vir Biotechnology has the market capitalization of 1.93B
When is the next Vir Biotechnology earnings date?▼
Vir Biotechnology is going to release the next earnings report on October 29, 2026.
What were Vir Biotechnology earnings last quarter?▼
VIR earnings for the last quarter are 0.47 USD per share, whereas the estimation was 0.33 USD resulting in a +41.31% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vir Biotechnology revenue for the last year?▼
Vir Biotechnology revenue for the last year amounts to 68.56M USD.
What is Vir Biotechnology net income for the last year?▼
VIR net income for the last year is -437.99M USD.
Does Vir Biotechnology pay dividends?▼
Yes, VIR dividends are paid quarterly. The last dividend per share was 0.03 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Vir Biotechnology have?▼
As of September 05, 2026, the company has 367 employees.
In which sector is Vir Biotechnology located?▼
Vir Biotechnology operates in the Health & Wellness sector.
When did Vir Biotechnology complete a stock split?▼
Vir Biotechnology has not had any recent stock splits.
Where is Vir Biotechnology headquartered?▼
Vir Biotechnology is headquartered in SAN FRANCISCO, United States.